Department of Anesthesiology, the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, China.
Hebei Provincial Cancer Institute, Shijiazhuang, Hebei 050011, China.
Discov Med. 2020 Nov-Dec;30(161):119-128.
Myeloid-derived suppressor cells (MDSCs) are immature suppressive cells partly influencing the efficacy of cancer immunotherapies. The crosstalk between MDSCs and immune cells mediates a potently immunosuppressive network within the tumor microenvironment to attenuate the anti-tumor response. Targeting MDSCs could be a potential therapeutic approach to overcome the limitation of immunotherapies. In this article, we will review available information on how MDSCs exert their immunosuppressive function and summarize the therapeutic strategies targeting them to enhance the efficacy of cancer immunotherapies.
髓源性抑制细胞（MDSCs）是一种不成熟的抑制性细胞，部分影响癌症免疫疗法的疗效。MDSCs 与免疫细胞之间的相互作用在肿瘤微环境中介导了一个强大的免疫抑制网络，从而削弱了抗肿瘤反应。靶向 MDSCs 可能是一种潜在的治疗方法，可以克服免疫疗法的局限性。本文将综述 MDSCs 发挥其免疫抑制功能的相关信息，并总结靶向 MDSCs 以增强癌症免疫疗法疗效的治疗策略。
Front Immunol. 2021-2-4
Pharmacol Res. 2016-5-6
Biochim Biophys Acta Rev Cancer. 2021-8
Cancer Immunol Res. 2021-3
Zotero 插件